Analyst David Vignon from Stifel Nicolaus maintained a Buy rating on Equasens (0R9T – Research Report) and keeping the price target at €75.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Vignon has given his Buy rating due to a combination of factors related to Equasens’s recent performance and future prospects. For the fourth quarter of 2024, Equasens’s revenue slightly exceeded expectations, marking a positive shift after several underwhelming quarters. This improvement is driven by the company’s strategic initiatives, including new product launches, a supportive regulatory environment, and a more favorable comparison basis.
Furthermore, Equasens’s valuation appears attractive at 8x EBITDA for 2025, suggesting the stock is undervalued given its growth potential. The company’s pharmacy business, which constitutes a significant portion of its revenue, has shown stable performance, and its recent acquisition of Digipharmacie is expected to continue growing. Additionally, the company is poised to benefit from the launch of the digital healthcare card in France, which could bolster its hardware solutions segment. Overall, these factors contribute to a positive outlook for Equasens, justifying the Buy rating.